RSS

 


04/02/2017

Publications

Genoscience Pharma to present data at the AACR Annual meeting 2017- Washigton, D.C. (Abstract n°1/2)

Abstract: Background: Hepatocellular carcinoma (HCC) remains a major health problem, often diagnosed atlate stages with limited number of therapeutic options. New drugs with original mechanisms ofaction are urgently aimed to improve current armamentarium in HCC patients. Quinoline derivativesare novel class of oral small molecules inducing multiple cellular effects such as inhibition ofautophagy, induction of apoptosis, and cell cycle… Lire la suite »

03/16/2017

Publications

Genoscience Pharma to present data at the 38th EORTC-PAMM Winter meeting_16th-18th March, Split, Croatia

Background: In spite of wide application of sorafenib for hepatocellular carcinoma (HCC) treatment, and systemic chemotherapy cocktails (5-fluorouracil, irinotecan, and oxaliplatin) for metastatic colorectal cancer, the prognostic for both cancers remains poor. In recent years, highly tumorigenic subpopulation of cancer cells named cancer stem cells (CSC) has been claimed as responsible of some tumor recurrences. Indeed, CSC are resistant… Lire la suite »

10/31/2016

Publications

Genoscience Pharma to present data on its promising candidate GNS561 at the Liver meeting 2016- AASLD

Abstract: Background: In spite of successful approval and wide application of sorafenib, the prognosis for patients with advanced hepatocellular carcinoma (HCC) remains poor. In recent years, highly tumorigenic sub‐populations of cancer cells named Cancer Stem Cells (CSCs) have been implicated in post‐treatment tumor recurrence. Indeed, CSCs are resistant to chemotherapy, and they have the ability to regenerate all the cell types… Lire la suite »

06/03/2016

Publications

Genoscience Pharma to present data on its most promising candidate GNS561 at the 2016 ASCO Annual Meeting

Abstract: In spite of successful approval and wide application of sorafenib, the prognosis for patients with advanced hepatocellular carcinoma (HCC) remains poor. In recent years, highly tumorigenic sub-populations of cancer cells named Cancer Stem Cells (CSCs) have been implicated in post-treatment tumor recurrence. Indeed, CSCs are resistant to chemotherapy, and they have the ability to regenerate all the cell types within the tumor.… Lire la suite »

02/25/2016

Publications

Cancer stem cells: Genoscience Pharma welcomes Pharmacyclics former senior management team to its board of directors

Marseille, February 24, 2016 – Genoscience Pharma, a biopharmaceutical company dedicated to discovering and developing cancer treatment drugs, today announces the arrival of four new members to its board of directors. Dr Mahkam Zanganeh, Robert Duggan and Manmeet Soni, respectively the former chief operating officer, chief executive officer and chief financial officer of Pharmacyclics, are joining the board along with Chaim Hurvitz,… Lire la suite »

07/30/2015

Genoscience Pharma to present data on its most promising candidate GNS561 at the Liver meeting 2015- AASLD

Abstract: Background: In spite of successful approval and wide application of sorafenib, the prognosis for patients with advanced hepatocellular carcinoma (HCC) remains poor. Fortunately, there have been renewed and continued interests and active research in developing other molecularly targeted agents in HCC during the past few years. While there is early evidence of antitumor activity of several agents in phase I/II studies, phase III… Lire la suite »

09/19/2014

Posters

26th EORTC-NCI-AACR SYMPOSIUM

Abstract: Despite efforts to understanding and treat acute myeloid leukemia (AML), there remains a need to more comprehensive therapies to prevent AML relapses and to reach sustainable clinical responses. To explain this phenomenon, the cancer stem cells/Leukemia initiating cells (CSCs/LICs) hypothesis suggests that tumors contain a small number of tumor-initiating cells, self-renewing cancer stem cells. Unlike most cells within the… Lire la suite »

07/30/2014

Publications

Oral treatment for Hepatitis C

BioLineRx Signs Exclusive License Agreement for BL-8020, an Oral Treatment for Hepatitis C BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience, a French companyfocused on viral disease therapeutics, to develop and commercialize BL-8020, an orally available treatment for Hepatitis C. BL-8020 has been… Lire la suite »